AU781805B2 - Inhibitors of the lectin complement pathway (LCP) and their use - Google Patents

Inhibitors of the lectin complement pathway (LCP) and their use Download PDF

Info

Publication number
AU781805B2
AU781805B2 AU66370/00A AU6637000A AU781805B2 AU 781805 B2 AU781805 B2 AU 781805B2 AU 66370/00 A AU66370/00 A AU 66370/00A AU 6637000 A AU6637000 A AU 6637000A AU 781805 B2 AU781805 B2 AU 781805B2
Authority
AU
Australia
Prior art keywords
mbl
receptor antagonist
complement activation
mbl receptor
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU66370/00A
Other languages
English (en)
Other versions
AU6637000A (en
Inventor
Robert Lekowski
Gregory L. Stahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of AU6637000A publication Critical patent/AU6637000A/en
Application granted granted Critical
Publication of AU781805B2 publication Critical patent/AU781805B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU66370/00A 1999-08-13 2000-08-14 Inhibitors of the lectin complement pathway (LCP) and their use Ceased AU781805B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14881599P 1999-08-13 1999-08-13
US60/148815 1999-08-13
PCT/US2000/022123 WO2001012212A1 (fr) 1999-08-13 2000-08-14 Inhibiteurs de la voie du complement a lectine (lpc) et utilisation de ceux-ci

Publications (2)

Publication Number Publication Date
AU6637000A AU6637000A (en) 2001-03-13
AU781805B2 true AU781805B2 (en) 2005-06-16

Family

ID=22527516

Family Applications (1)

Application Number Title Priority Date Filing Date
AU66370/00A Ceased AU781805B2 (en) 1999-08-13 2000-08-14 Inhibitors of the lectin complement pathway (LCP) and their use

Country Status (5)

Country Link
EP (1) EP1204419A1 (fr)
JP (1) JP2003507338A (fr)
AU (1) AU781805B2 (fr)
CA (1) CA2380979A1 (fr)
WO (1) WO2001012212A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US7273925B1 (en) 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
US7112414B2 (en) 2000-07-13 2006-09-26 Jens Christian Jensenius Masp-2, a complement-fixing enzyme, and uses for it
DE10130985B4 (de) * 2001-06-27 2004-03-18 B.R.A.H.M.S Ag Verfahren zur Diagnose von Sepsis und schweren Infektionen unter Bestimmung löslicher Cytokeratin-1-Fragmente
CN101897969B (zh) 2003-02-21 2014-04-02 健泰科生物技术公司 补体抑制剂在制备用于预防或抑制组织损伤的药物中的用途
SI2374819T1 (sl) 2003-05-12 2017-09-29 Helion Biotech Aps Protitelesa proteina MASP-2
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2006131874A2 (fr) * 2005-06-06 2006-12-14 Univ Cape Town Procedes de traitement ou de prophylaxie de l'atherosclerose et d'une lesion de reperfusion
US8524453B2 (en) 2006-02-10 2013-09-03 The Brigham And Woman's Hospital, Inc. Lectin complement pathway assays and related compositions and methods
US20110293524A1 (en) * 2008-02-29 2011-12-01 The Brigham and Women"s Hosptial Inc. Methods and compositions for the regulation of lectin complement pathway (lcp)-associated complement activation in hyperglycemic myocardial damage
CN106390117A (zh) 2009-10-16 2017-02-15 奥默罗斯公司 通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法
GEP20247583B (en) * 2015-11-09 2024-01-10 Univ Leicester Methods for treating condi tions associated with masp-2 dependent complement activation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500023L (sv) * 1994-05-17 1995-11-18 Beki Ab Sätt att detektera cancer
DE19806185C2 (de) * 1998-02-02 1999-11-18 Biogenes Gmbh Immunoassay und Testkit zur Bestimmung von fucosyliertem Protein in einer biologischen Probe
EP1140171A4 (fr) * 1998-12-15 2002-03-13 Brigham & Womens Hospital Techniques et produits permettant de reguler l'activation du complement associee a la voie du complement a lectine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COLLARD C.D ET AL, FASEB JOURNAL (1998) VOL 12 (4) PP A29 *
COLLARD C.D ET AL, MOLECULAR IMM. (1999) VOL 36 (4-5) P 278 *

Also Published As

Publication number Publication date
EP1204419A1 (fr) 2002-05-15
JP2003507338A (ja) 2003-02-25
AU6637000A (en) 2001-03-13
CA2380979A1 (fr) 2001-02-22
WO2001012212A1 (fr) 2001-02-22

Similar Documents

Publication Publication Date Title
US20230112931A1 (en) Plasma kallikrein binding proteins
AU781805B2 (en) Inhibitors of the lectin complement pathway (LCP) and their use
CA2597717C (fr) Anticorps contre cxcr4 et leurs procedes d'utilisation
US6962813B2 (en) P. aeruginosa mucoid exopolysaccharide specific binding peptides
EP2209485B1 (fr) Histones extracellulaires en tant que biomarqueurs pour un pronostic et cibles moléculaires pour une thérapie
US20180021430A1 (en) Selective targeting of the cd40l/mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
US20060235206A1 (en) P. aeruginosa mucoid exopolysaccharide specific binding peptides
EP2217238B1 (fr) Procédés et compositions pour le traitement de maladies protéinuriques
US7273925B1 (en) Methods and products for regulating lectin complement pathway associated complement activation
KR20150035354A (ko) 보체 관련 질환의 예방 및 치료를 위한 ｃ5 항체 및 방법
CN102985106A (zh) 用于治疗德戈斯病的方法和组合物
JP2016539121A (ja) 血管新生抑制活性を有するペプチド、及びそれを含む組成物
WO2000035483A1 (fr) Techniques et produits permettant de reguler l'activation du complement associee a la voie du complement a lectine
US7662382B2 (en) Inducible ligand for α1β1 integrin and uses
US20210179717A1 (en) Antibodies against mac-1
TWI432211B (zh) 與登革病毒相關之胜肽及抗體以及其用途
US20080274955A1 (en) Novel Use of a Polypeptide Comprising Fas-1 Domain
RU2778566C1 (ru) Полипептид для лечения патологических тромбов
KR101268562B1 (ko) Ｔｌｔ-6 단백질에 대한 항체 및 그 응용
Chen A new regulatory function for C1 inhibitor